PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (November 2025)
31 slides from PetVivo's investor presentation, Nov 3, 2025
Slide 1: Investor Presentation November 2025
Investor Presentation November 2025 PETV (OTCQX)
Slide 2: Forward-Looking Statements
Forward-Looking Statements PETYIVO This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially fr
Slide 3: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary care and product sales market with ~ 6% historical CAGR (2020-2024)* Commercialized Regenerative Product Portfoli Spryng®, with OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechani
Slide 4: Osteoarthritis: a common affliction of the joints
Osteoarthritis: acommon affliction of the joints e Affects approximately 34 million adult dogs and 1 million horses* e@ Causes pain and inflammation from degenerated cartilage of stressed joints e@ Lameness worsens with time from ongoing loss of cartilage and the presence of inflammation in the join
Slide 5: Viscosupplementation
Viscosupplementation A strong hydrated biomaterial that facilitates enhanced Lubrication and joint-cushioning properties. € Micro-scaffolds Over time, micro-scaffolds adhere to and integrate with the existing synovial membrane. Collagen-Elastin Microparticles Porous, spongy particles absorb and rele
Slide 6: An Optimal OA Solution: Spryng with OsteoCushion Technology
An Optimal OA Solution: Spryng® with OsteoCushion Technology e Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function © Similar components/function found in natural cartilage (i.e. collagen, elastin and hep
Slide 7: Spryng with OsteoCushion Technology
Spryng® with OsteoCushion® Technology e Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms e Purified natural components self-assemble to form an insoluble, hydrated matrix e Protein source bovine tissues (i.e. medical grade collagen and elastin)
Slide 8: Spryng Mechanism of Action
Spryng Mechanism of Action e Ananimal suffering from osteoarthritis generally exhibits damaged and/or Lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain, and further loss of cartilage. e Spryng reinforces synovial membrane function, without p
Slide 9: Spryng Canine Success: Cooper
Spryng® Canine Success: Cooper Treatment e@ On January 14, 2025, Cooper received Spryng® with OsteoCushion™ Technology injections in both elbows. Condition 7-year-old mixed-breed dog. Diagnosed with severe arthritis in both elbows in March 2024. e After injection, the elbows were moved through a ran
Slide 10: Spryng Equine Success
Spryng® Equine Success: History Results! 16-year-old Saddlebred e Mild improvement after mare. one week. Fergie shows asa e After one month, Saddlebred monthly and substantially smoother ridden 5-6 days per week. gait, although some stiffness remaining in However, due to apparent left rear leg. disc
Slide 11: Spryng Competitive Distinctions
Spryng Competitive Distinctions e@ Outcomes address affliction/not just symptoms e Current treatments rely on biologic activity to treat symptoms; Spryng provides structural components to address affliction Price/Cost advantage Derived from all natural materials Ease of application Vet clinic exclus
Slide 12: Spryng Product Category Comparison
Spryng® Product Category Comparison Features Injections per Year Benefits Last up to 12 Months or More Bioscaffold From Naturally-Derived Components No Synthetic or Radioactive Material Research Supports Joints Health Benefits No Drug Interactions & No Systemic Effects (Medical Device) Alll Stages o
Slide 13: Spryng Tolerance Studies
Spryng® Tolerance Studies Ne . Feline Tolerance Purpose: Assess tolerance of Spryng™ administration in cats. Design: 10 healthy female cats received intra- articular injection with saline or Spryng in contralateral shoulder, hip, elbow, and stifle joints in a randomized sequence. Two-week washout pe
Slide 14: Spryng Clinical Studies
Spryng® Clinical Studies CanineHipOA CASE ETHOS Purpose: Study the effects of Collagen-Elastin Hydrogel Microparticles (Spryng) on pain & function secondary to hip osteoarthritis in dogs. Investigators: Colorado Animal Specialty & Emergency with Ethos Veterinary Health Design: Using Simon’s Two-Stag
Slide 15: New Spryng Clinical Trials
New Spryng® Clinical Trials Underway or Recently Completed, Awaiting Publication Canine Study at Colorado State University Principal investigators: Felix Duerr, DVM, MS, Dr. med. vet., CCRT, DACVS-SA, DECVS, DACVSSMR Pilot study design: Pilot study evaluating intra-articular injection of a hydrophil
Slide 16: PrecisePRP: No Centrifuge Required
No Centrifuge Required Freeze-dried, pooled, leukoreduced, RBC removed, allogeneic. No Blood Draw Sterility, endotoxin and mycoplasma evaluated every time. () Consistent Dosing Platelet Derived Growth Factor (PDGF-BB) measured in every batch. Total platelet dose per vial equals 4 billion platelets.
Slide 17: What is Platelet-Rich Plasma (PRP)?
What is Platelet-Rich Plasma (PRP)? e The most common regenerative therapy utilized in veterinary medicine. e Concentrated preparation of platelets and plasma. e First published use in the 1970’s as an intralesional and fracture repair product in horses and dogs. e Benefits of PRP o Many publication
Slide 18: Common Uses of Platelet-Rich Plasma in Veterinary Medicine
Common Uses of Platelet-Rich Plasma in Veterinary Medicine In Conjunction with Stem Cell Therapy Wound Healing Post Surgical Healing Dental and Oral Surgical Procedures Ophthalmic Uses e Corneal Ulceration e Keratoconjunctivitis Sicca e Descemetocele Musculoskeletal Disease/Injury e Osteoarthritis e
Slide 19: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities e Spryng® product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 e Initial batch sizes of approx. 500 syringes; planning to increase to batches of 5,000+ syringes per month. e Current production facility annual capacity is approx
Slide 20: Comprehensive IP Portfolio US and Foreign Issued Patents
Comprehensive IP Portfolio 12 US and Foreign Issued Patents Broad Claim Language - “Comprising” Transitions 6 Detailed Proprietary Trade Secrets Our Patents & Trade Secrets Protect: Protein & Carbohydrate Based Thermoplastics Biomaterials of Many Compositions Medical, Drug Delivery & Combination Pro
Slide 21: Market Overview
Sources: American Pet Products Assoc.; North M a r ket Ove rv i ew American Pet Health Insurance Association, American Horse Council, LendEDU Companion Animal/Veterinarian * Agricultural and professional equine markets not included e US Pet Spend increased from $152B in 2024 to $157B in 2025 e Veter
Slide 22: Pet Product Pipeline
Pet Prod uct Pipel i ne No FDA Review or Clearance Required for FDA clearance not required Commercialization of Veterinary Medical Devices — “Tauck VD-08 Osteoarthritis Canine (SmartSpryng™) » VD-09 Osteoarthritis Equine (SmartSpryng™) »D VD-05 Osteoarthritis Feline (Spryng®) Se 932023 9 Canine, Equ
Slide 23: Distribution Partners
Distribution Partn MWI Animal Health* cencora MWI Animal Health MWI - PetVivo Distribution Services Agreement Terms: e Non-exclusive distribution agreement with ongoing annual renewal option until terminated by either party e Designated distributor for PetVivo’s veterinary medical device, Spryng wit
Slide 24: Wholesale Partners
Wholesale Partners I Health AV£=Yo [oxe) Vedco —- Wholesaler Engagement: e Wholesaler relationship to purchase product from PetVivo and sell it to national distributors for subsequent sale to U.S. vets e Designated wholesaler for PetVivo’s veterinary medical device, Spryng® with OsteoCusion® Technol
Slide 25: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Relationship - Strategic Alliance Agreement: PetVivo shall: i) invest in and sponsor the Agentics Al Framework for all PetVivo customers, ii) market the Al Framework technology to all PetVivo veterinary partners and pet owner customers, iii
Slide 26: PetVivo Strategic Partners
PetVivo Strategic Partners PiezoBioMembrane, Inc. (“PBM”) and Veterinary Growth Partners (“VGP”) PBM (Functional Biomaterials) Relationship — Master Services Agreement (Joint R&D): Collaboration on the research and development of a novel piezo biomaterials for therapeutic applications (e.g Smart-Spr
Slide 27: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience John Lai Garry Lowenthal John F. Dolan April Boyce CEO, President & Director CFO General Counsel VP of Sales & Marketing 2) Bluezarth a J rte pwe 4 TRAusT TRAUST P&G Fredrikson a> en Deloitte. Kirsty Husby, DVM,
Slide 28: Strong Independent Board of Directors and Advisors
Strong Independent Board of Directors and Advisors Advisors Dr. Tracy Turner, DVM, MS, Dipl. ACVS, Dipl. ACSMR, Amer. Academy Thermology, AAEP Board Dr. Sherman Cannap, DVM, MS, CCRT, DACVS-SA, DACVSMR, Cannap Sports Medicine, Orthobiologic Innovations Dr. Debra Cannap, DVM, CCRT, CVA, DACVSMR, Cann
Slide 29: Growth Drivers
Growth Drivers Sales Growth & Expansion e US Direct Veterinary Sales Force e 100% US veterinary market coverage via established distributor network. e International expansion; UK/MX (2025) CA/EU expected CY2026. @ Momentum and growth in clinic adoption and use cases delivering ~ 17% increase in our
Slide 30: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary care and product sales market with ~ 6% historical CAGR (2020-2024)* Commercialized Regenerative Product Portfolio Spryng®, with OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechan
Slide 31: John Lai
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 Spryng® with OsteoCushion™ Technology and PrecisePRP™ are exclusively sold and distributed by PetVivo Animal Health. Veterinary Use Only - Federal law restricts this device to use by or on the order of a licensed veterinarian. 844-Pet-
PetVivo Holdings — Investor Presentation (November 2025) on 6ix